TMIC-13. GLIOMA-DRIVEN DENDRITIC CELL DYSFUNCTION AS AN IMMUNE EVASION STRATEGY AGAINST ADOPTIVE CELLULAR THERAPY

Abstract BACKGROUND Our previous studies has developed an adoptive cellular therapy (ACT) against high grade gliomas in both human and murine systems. ACT significantly improves survival models of CNS malignancies. have shown that efficacy is associated with the observed increase tumor-associated dendritic cells (DC) which arise from transferred hematopoietic stem (HSC). HSC-derived DCs play a pivotal role mounting anti-tumor immune response. In this study, we identified treatment resistance may be due to glioma-driven cell dysfunction. We significant down regulation co-stimulatory markers on mice escaped subsequent capacity activate tumor-reactive T cells.Method: KR158B bearing received HSC tumor reactive one day before 9 Gy irradiation followed by 3 does BMDC vaccine. Tumor were sorted tumors evaded co-cultured primary or cells. proliferation interferon gamma detected for comparison. PCR array was performed identify dysregulated functional genes.Results CONCLUSIONS Functional evidence demonstrated resistant had decreased activating either glioma generated target ACT. Gene expression data showed decreases genes co-stimulation, engagement, antigen presentation.